Involvement of autophagy in cervical, endometrial and ovarian cancer

International Journal of Cancer

Volumn 135, Issue 3, 2014, Pages 519-528

  Orfanelli, T ^a   Jeong, J M ^a   Doulaveris, G ^a   Holcomb, K ^a   Witkin, S S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Autophagy; Cervical cancer; Chemotherapy; Endometrial cancer; Ovarian cancer

Indexed keywords

BECLIN 1; LIGHT CHAIN 3; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICROTUBULE ASSOCIATED PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CELL SURVIVAL; CHEMOSENSITIVITY; DISEASE ASSOCIATION; DRUG TARGETING; ENDOMETRIUM CANCER; HUMAN; NONHUMAN; OVARY CANCER; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER;

AUTOPHAGY; CERVICAL CANCER; CHEMOTHERAPY; ENDOMETRIAL CANCER; OVARIAN CANCER;

ANTINEOPLASTIC AGENTS; AUTOPHAGY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MALE; OVARIAN NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 84901001901     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28524     Document Type: Review

References (89)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Choi AM, Ryter SW, Levine B,. Autophagy in human health and disease. N Engl J Med 2013; 368: 651-62.
3. Martinet W, Agostinis P, Vanhoeke B, et al. Autophagy in disease: a double-edged sword with therapeutic potential. Clin Sci 2009; 116: 697-712.
4. Kimmelman AC,. The dynamic nature of autophagy in cancer. Genes Dev 2011; 25: 1999-2010.
5. White E,. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012; 12: 401-10.
6. Kondo Y, Kanzawa T, Sawaya R, et al. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005; 5: 726-34.
7. Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006; 10: 51-64.
8. Gozuacik D, Kimchi A,. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004; 23: 2891-906.
9. Cheng HY, Zhang YN, Wu QL, et al. Expression of beclin 1, an autophagy-related protein, in human cervical carcinoma and its clinical significance. Eur J Gynaecol Oncol 2012; 33: 15-20.
10. Zhu W, Pan X, Li F, et al. Expression of Beclin 1 and LC3 in FIGO stage I-II cervical squamous cell carcinoma and relationship to survival. Tumour Biol 2012; 33: 1653-9.
11. Chen TC, Hung YC, Lin TY, Chang HW, Chiang IP, Chen YY, Chow KC,. Human papillomavirus infection and expression of ATPase family AAA domain containing 3A, a novel anti-autophagy factor, in uterine cervical cancer. Int J Mol Med 2011; 28: 689-96.
12. Sivridis E, Giatromanolaki A, Liberis V, et al. Autophagy in endometrial carcinomas and prognostic relevance of 'stone-like' structures (SLS): what is destined for the atypical endometrial hyperplasia? Autophagy 2011; 7: 74-82.
13. Giatromanolaki A, Koukourakis MI, Koutsopoulos A, et al. High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas. Gynecol Oncol 2011; 123: 147-51.
14. Deng L, Broaddus RR, McCampbell A, et al. Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer. Clin Cancer Res 2005; 11: 8258-64.
15. Shen Y, Li DD, Wang LL, et al. Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer. Autophagy 2008; 4: 1067-8.
16. Duan ZL, Peng ZL, Wang ZH,. Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer. Sichuan Da Xue Xue Bao Yi Xue Ban 2007; 38: 239-42.
17. Park SM, Kim K, Lee EJ, et al. Reduced expression of DRAM2/TMEM77 in tumor cells interferes with cell death. Biochem Biophys Res Commun 2009; 390: 1340-4.
18. He C, Levine B,. The Beclin 1 interactome. Curr Opin Cell Biol 2010; 22: 140-9.
19. Bunkholt Elstrand M, Dong HP, Ødegaard E, et al. Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum Pathol 2010; 41: 794-804.
20. De Marco C, Rinaldo N, Bruni P, et al. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma. PLoS One 2013; 8: e55362.
21. Kolasa IK, Rembiszewska A, Janiec-Jankowska A, et al. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecol Oncol 2006; 103: 692-7.
22. Arico S, Petiot A, Bauvy C, et al. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 2001; 276: 35243-6.
23. Kulbe H, Thompson R, Wilson JL, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007; 67: 585-92.
24. Bartholomeusz C, Rosen D, Wei C, et al. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res 2008; 68: 9302-10.
25. Yu Y, Xu F, Peng H, et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 1999; 96: 214-9.
26. Rosen DG, Wang L, Jain AN, et al. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res 2004; 10: 6559-66.
27. Lu Z, Luo RZ, Lu Y, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 2008; 118: 3917-29.
28. Lane D, Matte I, Rancourt C, et al. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011; 11: 210.
29. Coward J, Kulbe H, Chakravarty P, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 2011; 17: 6083-96.
30. Zhao JH, Wan XY, Xie X, et al. Expression and clinical significance of Beclin1 and PTEN in endometrial carcinoma. Ai Zheng 2006; 25: 753-7.
31. Eskelinen EL, Saftig P,. Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim Biophys Acta 2009; 1793: 664-73.
32. Yue Z, Jin S, Yang C, et al. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 2003; 100: 15077-82.
33. Klionsky DJ, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445-544.
34. Zhou S, Zhao L, Kuang M, et al. Autophagy in tumorigenesis and cancer therapy: Dr.Jekyll or Mr.Hyde? Cancer Lett 2012; 323: 115-27.
35. Gozuacik D, Kimchi A,. Autophagy and cell death. Curr Top Dev Biol 2007; 78: 217-45.
36. Maiuri MC, Zalckvar E, Kimchi A, et al. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8: 741-52.
37. Chauhan S, Jaggi M, Bell M, et al. Epidemiology of human papillomavirus in cervical mucosa. Methods Mol Biol 2009; 471: 439-56.
38. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009; 9: 347-56.
39. Ibeanu OA,. Molecular pathogenesis of cervical cancer. Cancer Biol Ther 2011; 11: 295-306.
40. Wang ZH, Xu L, Duan ZL, et al. Beclin 1-mediated macroautophagy involves regulation of caspase-9 expression in cervical cancer HeLa cells. Gynecol Oncol 2007; 107: 107-13.
41. Sun Y, Liu JH, Sui YX, et al. Beclin1 overexpression inhibitis proliferation, invasion and migration of CaSki cervical cancer cells. Asian Pac J Cancer Prev 2011; 12: 1269-73.
42. Sun Y, Liu JH, Pan L, et al. Modulatory effects of Beclin 1 on expression of angiopoietin and Tie-2 receptor in human cervical cancer cells. Asian Pac J Cancer Prev 2011; 12: 2985-90.
43. Wang ZH, Xu L, Wang Y, et al. Clinicopathologic correlations between human papillomavirus 16 infection and Beclin 1 expression in human cervical cancer. Int J Gynecol Pathol 2011; 30: 400-6.
44. Rosa DD, Medeiros LR, Edelweiss MI, et al. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev 2012; 6:CD005342.
45. Yee GP, de Souza P, Khachigian LM,. Current and potential treatments for cervical cancer. Curr Cancer Drug Targets 2013; 13: 205-20.
46. Lee SB, Tong SY, Kim JJ, et al. Caspase-independent autophagic cytotoxicity in etoposide-treated CaSki cervical carcinoma cells. DNA Cell Biol 2007; 26: 713-20.
47. Xiao X, He Q, Lu C, et al. Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol Oncol 2012; 127: 249-55.
48. Cui Q, Tashiro S, Onodera S, et al. Oridonin induced autophagy in human cervical carcinoma HeLa cells through Ras, JNK, and P38 regulation. J Pharmacol Sci 2007; 105: 317-25.
49. Zhang YH, Wu YL, Tashiro S, et al. Reactive oxygen species contribute to oridonin-induced apoptosis and autophagy in human cervical carcinoma HeLa cells. Acta Pharmacol Sin 2011; 32: 1266-75.
50. Hsu KF, Wu CL, Huang SC, et al. Cathepsin L mediates resveratrol-induced autophagy and apoptotic cell death in cervical cancer cells. Autophagy 2009; 5: 451-60.
51. Fels DR, Ye J, Segan AT, et al. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res 20085; 68: 9323-30.
52. Sun Y, Zhang J, Peng ZL,. Beclin1 induces autophagy and its potential contributions to sensitizing SiHa cells to carboplatin therapy. Int J Gynecol Cancer 2009; 19: 772-6.
53. Sun Y, Jin L, Liu J, et al. Effect of autophagy on paclitaxel-induced CaSki cell death. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2010; 35: 557-65.
54. Sun Y, Liu JH, Jin L, et al. Over-expression of the Beclin1 gene upregulates chemosensitivity to anti-cancer drugs by enhancing therapy-induced apoptosis in cervix squamous carcinoma CaSki cells. Cancer Lett 2010; 294: 204-10.
55. Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Available at: http://seer.cancer.gov/faststats.
56. Dong P, Kaneuchi M, Konno Y, et al. Emerging therapeutic biomarkers in endometrial cancer. Biomed Res Int 2013; 2013: 130362.
57. Petiot A, Ogier-Denis E, Blommaart EF, et al. Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem 2000; 275: 992-8. Erratum in:J Biol Chem 2000;275:12360.
58. Deng L, Feng J, Broaddus RR,. The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress. Cell Death Dis 2010; 1: e32.
59. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999; 402: 672-6.
60. Yoon JH, Her S, Kim M, et al. The expression of damage-regulated autophagy modulator 2 (DRAM2) contributes to autophagy induction. Mol Biol Rep 2012; 39: 1087-93.
61. Crighton D, Wilkinson S, O'Prey J, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006; 126: 121-34.
62. Bast RC Jr, Hennessy B, Mills GB,. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9: 415-28.
63. Spowart JE, Townsend KN, Huwait H, et al. The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer. J Pathol 2012 Aug 27.
64. Luo RZ, Fang X, Marquez R, et al. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 2003; 22: 2897-909.
65. Badgwell DB, Lu Z, Le K, et al. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene 2012; 31: 68-79.
66. Chen K, Rajewsky N,. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 2007; 8: 93-103.
67. Boren T, Xiong Y, Hakam A, et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009; 113: 249-55.
68. Mezzanzanica D, Bagnoli M, De Cecco L, et al. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol 2010; 42: 1262-72.
69. Vaksman O, Stavnes HT, Kaern J, et al. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med 2011; 15: 1593-602.
70. Zhu H, Wu H, Liu X, et al. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy 2009; 5: 816-23.
71. Frankel LB, Wen J, Lees M, et al. microRNA-101 is a potent inhibitor of autophagy. EMBO J 2011; 30: 4628-41.
72. Marchini S, Cavalieri D, Fruscio R, et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol 2011; 12: 273-85.
73. 1). Pharm Res 2011; 28: 3079-90.
74. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-33.
75. Lou Y, Yang X, Wang F, et al. MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Int J Mol Med 2010; 26: 819-27.
76. Chou CH, Wei LH, Kuo ML, et al. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. Carcinogenesis 2005; 26: 45-52.
77. Yu S, Murph MM, Lu Y, et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008; 100: 1630-42.
78. Delk NA, Farach-Carson MC,. Interleukin-6: a bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells. Autophagy 2012; 8: 650-63.
79. Chang CL, Liao JJ, Huang WP, et al. Lysophosphatidic acid inhibits serum deprivation-induced autophagy in human prostate cancer PC-3 cells. Autophagy 2007; 3: 268-70.
80. Eustace AJ, Crown J, Clynes M, et al. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med 2008; 6: 53.
81. Tsao AS, He D, Saigal B, et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 2007; 6: 1962-72.
82. Le XF, Mao W, Lu Z, et al. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 2010; 116: 4980-90.
83. Liu N, Tai S, Ding B, et al. Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis. Endocr Relat Cancer 2012; 19: 711-23.
84. Chen MY, Liao WS, Lu Z, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer 2011; 117: 4424-38.
85. Bast RC, Jr., Molecular approaches to personalizing management of ovarian cancer. Ann Oncol 2011; 22 (Suppl 8): viii5-viii15.
86. Zhang N, Qi Y, Wadham C, et al. FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy. Autophagy 2010; 6: 1157-67.
87. Zhang Y, Cheng Y, Ren X, et al. NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response. Oncogene 2012; 31: 1055-64.
88. Liang B, Kong D, Liu Y, et al. Autophagy inhibition plays the synergetic killing roles with radiation in the multi-drug resistant SKVCR ovarian cancer cells. Radiat Oncol 2012; 7: 213.
89. Kong D, Ma S, Liang B, et al. The different regulatory effects of p53 status on multidrug resistance are determined by autophagy in ovarian cancer cells. Biomed Pharmacother 2012; 66: 271-8.